First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer

Autor: Blagden, Sarah, Omlin, Aurelius, Olmin, Aurelius, Josephs, Debra, Stavraka, Chara, Zivi, Andrea, Pinato, David J, Anthoney, Alan, Decordova, Shaun, Swales, Karen, Riisnaes, Ruth, Pope, Lorna, Noguchi, Kohei, Shiokawa, Rie, Inatani, Michiyasu, Prince, Jenny, Jones, Keith, Twelves, Chris, Spicer, James, Banerji, Udai

Publikováno v: Blagden, S, Omlin, A, Olmin, A, Josephs, D, Stavraka, C, Zivi, A, Pinato, D J, Anthoney, A, Decordova, S, Swales, K, Riisnaes, R, Pope, L, Noguchi, K, Shiokawa, R, Inatani, M, Prince, J, Jones, K, Twelves, C, Spicer, J & Banerji, U 2014, ' First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer ', Clinical Cancer Research, vol. 20, no. 23, pp. 5908-17 . https://doi.org/10.1158/1078-0432.CCR-14-1315

Purpose: This phase I dose-escalation study investigated the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of CH5132799. Experimental Design: Pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7170e899ec5512a80f4b7a94dca09564
https://kclpure.kcl.ac.uk/en/publications/54022859-30c8-4a45-b639-ef70bccc57d8